A) Mice were orthotopically injected with M3-9-M ffluc-mCherry-OVA tumors. Mice received either no treatment (n=10), 7.4×106 OT-I T cells (n=11), 3.5×106 IL12-GEMy (n=11), or both (n=11) intravenously on day 12. B) Mice were orthotopically injected with M3-9-M ffluc-mCherry-OVA and treated with 2 mg of cyclophosphamide and 5 mg of fludarabine i.p. on day 8. Mice received 5×106 IL12-GEMys intravenously on day 10. Survival and tumor growth were monitored over time (no treatment n=10, Cy/Flu n=9, Cy/Flu + IL12-GEMy n=10). IL12-GEMy-cured mice were re-challenged with C) unlabeled M3-9-M cells or D) M3-9-M ffluc-mCherry-OVA in the contralateral leg compared to naïve age-matched controls (n=5). E) Mice were orthotopically injected with M3-9-M ffluc-mCherry tumor, treated with 2 mg of cyclophosphamide and 5 mg of fludarabine i.p. on day 10, and 8×106 IL12-GEMys on day 12. Anti-IL12 or Rat IgG isotype antibody was administered starting on day 12 and every 5 days for the duration of the experiment (n=10). Survival data were tested for significance by Log-rank (Mantel-Cox) test. See also Figure S7.